Brief: Kazia Reports Ex Vivo Disruption of Tumor Cell Clusters in Stage IV HER2+ Breast Cancer with Paxalisib Monotherapy
11/09/2025 13:42
Sept 11 (Reuters) - Kazia Therapeutics Ltd KZIA.O: KAZIA THERAPEUTICS REPORTS COMPLETE EX VIVO DISRUPTION OF LARGE CIRCULATING TUMOR CELL CLUSTERS IN STAGE IV HER2-POSITIVE BREAST CANCER WITH PAXALISIB MONOTHERAPY Source text: ID:nPn1sdGKDa Further company coverage: KZIA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
Kazia drops on $40 mln equity offering to fund breast cancer drug
Kazia slides after breast cancer drug update, equity offering launch
Brief: Kazia Therapeutics Limited Announces Proposed Public Offering